Novartis has appointed Shaun Coughlin to head up its biomedical research institute based in Cambridge, Massachusetts, as its new global head of cardiovascular and metabolism.
He joins the pharma giant from the University of California San Francisco’s (UCSF) cardiovascular research centre, where he was previously a director. He has served UCSF for 33 years.
Talmadge King Jr, dean, school of medicine at USFC, said: “We are sad to lose on our most respected leaders, yet profoundly grateful for his decades of service and immeasurable contributions to our mission.
“Dr Coughlin is an outstanding example of the personal qualities that collectively have propelled UCSGF to the top.”
Coughlin is also a member of the National Academy of Scienes, the National Academy of Medicine and the American Academy of Arts & Scienes and has won numerous awards including Brisol-Myers Squibb’s Cardiovascular Research Award.